Related Experiment Videos
Myelodysplastic syndromes in childhood: description of seven cases
A Vitale1, A M Testi, M L Moleti
1Department of Human Biopathology, University La Sapienza, Rome, Italy.
Insights
Managing pediatric myelodysplastic syndromes (MDS) is challenging. While some children with MDS survive long-term with supportive care, others progress to acute myeloid leukemia, often with fatal outcomes despite intensive treatment.
Area of Science:
- Pediatric Hematology
- Oncology
- Malignant Hematology
Background:
- Primary myelodysplastic syndromes (MDS) are rare in children.
- Understanding the natural history and treatment outcomes in pediatric MDS is crucial for improving patient management.
Observation:
- Seven children diagnosed with primary myelodysplastic syndromes over nine years were analyzed.
- Presenting subtypes included refractory anemia, refractory anemia with excess of blasts, and refractory anemia with excess of blasts in transformation.
- Supportive therapy, including blood transfusions, was administered to most patients.
Findings:
- Three patients progressed to acute myeloid leukemia (AML) and received intensive chemotherapy and stem cell transplantation.
- All three patients who developed AML died from infection or disease progression.
- The remaining four patients remain alive, with a median follow-up of 71 months.
Implications:
- Pediatric myelodysplastic syndromes present significant management challenges.
- Outcomes vary widely, with a subset progressing to AML and experiencing poor survival.
- Further research is needed to optimize treatment strategies for children with MDS.
Abstract:
Seven children with a primary myelodysplastic syndrome were seen at our center over a 9-year period. Two presented with refractory anemia, three with refractory anemia with excess of blasts, and two with refractory anemia with excess of blasts in transformation. All children received supportive therapy, including blood transfusions in five of them. Three patients developed acute myeloid leukemia and were treated with intensive chemotherapy, followed by allogeneic or autologous marrow transplantation in the two responders. All three died of either infection or progressive disease. The other four patients are still alive a median of 71 months (range 38-130) after diagnosis. These results confirm the difficulties in managing patients with myelodysplastic syndromes.